
    
      This is a 2-week, multicenter, randomized, double-blind, placebo-controlled, parallel group,
      efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and
      premenarchal female subjects 6 to 11 years-old diagnosed with SAR.

      This study will consist of the following:

      Screening, Single-blind Placebo Run-in period, Double-blind Treatment period (during this
      period, subjects will be randomized to double-blind treatment with either ciclesonide nasal
      aerosol 37 mcg or 74 mcg or placebo for 2 weeks of treatment) and Follow-up. The total
      duration of subject participation will be approximately 2 months.
    
  